The Scientist

Detecting the Cell-Free DNA Fragmentome of Ovarian Cancer

Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
News Medical

Elegen and Nutcracker Therapeutics to pilot first fully cell-free manufacturing process for RNA-based personalized cancer therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...

Novel liquid biopsy technology lowers barriers for more efficient cancer diagnostics

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing ...

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 ...
The University of Chicago Chronicle

Innovative liquid biopsy test uses RNA to detect early-stage cancer

A new liquid biopsy developed by researchers at the University of Chicago is offering a powerful new window into cancer’s earliest stages by flagging subtle shifts in the gut microbiome. Unlike ...